RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

References

• Aleksandra A, Omar E, Aikaterini E, et al. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul. 2017;68:77–87. doi:10.1016/j.jbior.2017.11.00729221990
   PubMedGoogle Scholar
• Ma JL, Hui PP, Meng WY, et al. Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis. Biochem Biophys Res Commun. 2017;484:746–752. doi:10.1016/j.bbrc.2017.01.14628153717
   PubMedGoogle Scholar
• Lucas DSC, Gisele M. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16. doi:10.1016/j.ejphar.2014.07.04125084222
   PubMedGoogle Scholar
• Maria GC, Celine P, Philip WI, et al. Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer. Eur J Pharm Sci. 2018;115:296–303. doi:10.1016/j.ejps.2018.01.03329366960
   PubMedGoogle Scholar
• Chi VD. MUC-king with HIF may rewire pyrimidine biosynthesis and curb gemcitabine resistance in pancreatic cancer. Cancer Cell. 2017;32:3–5. doi:10.1016/j.ccell.2017.06.00628697341
   PubMedGoogle Scholar
• Jia YF, Xie JW. Promising molecular mechanisms responsible for gemcitabine resistance in cancer. Genes Dis. 2015;2:299–306. doi:10.1016/j.gendis.2015.07.00330258872
   PubMedGoogle Scholar
• Jessica GJ, Carlos M, Pankaj G, et al. Fatal acute cardiac vasculopathy during cisplatin-gemcitabine-bevacizumab (CGB) chemotherapy for advanced urothelial carcinoma. J Infect Chemother. 2016;22:112–116. doi:10.1016/j.jiac.2015.08.01526423690
   PubMedGoogle Scholar
• Metin U, Manisha K, Ramesh P, et al. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer. J Control Release. 2019;294:237–246. doi:10.1016/j.jconrel.2018.12.03130576747
   PubMedGoogle Scholar
• Fernando R, Manuel B, Javier G, et al. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study. Pancreatology. 2019;19:64–72.
   Web of Science ®Google Scholar
• Yeo WK, Ji EL, Kyung HJ, et al. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Cancer Lett. 2018;348:174–186.
   Google Scholar
• Qian WK, Li J, Chen K, et al. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sci. 2018;208:253–261. doi:10.1016/j.lfs.2018.07.04630053447
   PubMed Web of Science ®Google Scholar
• Lou CJ, Lu HB, Ma ZG, et al. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway. Biomed Pharmacother. 2019;109:563–572. doi:10.1016/j.biopha.2018.10.084
   PubMed Web of Science ®Google Scholar
• AnnaL S, NP K, Marta G, et al. Melatonin and its metabolite N1-acetyl-N2-formyl-5- methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1). Pharmacol Rep. 2018;70:1079–1088. doi:10.1016/j.pharep.2018.05.00730308458
   PubMedGoogle Scholar
• Sunny G, Rahul JS, Ved B, et al. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: experience over the last decade. Asian J Urol. 2019;6:222–229.
   Web of Science ®Google Scholar
• Claudio V, Michele P, Monica M, et al. Single-agent gemcitabine vs. carboplatin-gemcitabine in advanced breast cancer: a retrospective comparison of efficacy and safety profiles. Clin Breast Cancer. 2019;19:306–318.
   Web of Science ®Google Scholar
• Michael EH, Paul M, Yao XP, et al. Multicenter phase 2 trial of gemcitabine, carboplatin, and sorafenib in patients with metastatic or unresectable transitional-cell carcinoma. Clin Genitourin Cancer. 2018;16:437–444. doi:10.1016/j.clgc.2018.07.02130177237
   PubMedGoogle Scholar
• Hayley SM, Graham M, Robert H, et al. Salvage chemotherapy with gemcitabine, paclitaxel, ifosfamide, and cisplatin for relapsed germ cell cancer. Clin Genitourin Cancer. 2018;16(6):458–465. doi:10.1016/j.clgc.2018.07.00630115544
   PubMedGoogle Scholar
• Hiroki F, Hiroshi K, Hisashi K, et al. Successful treatment with paclitaxel, carboplatin, and gemcitabine as second-line chemotherapy for recurrent urothelial carcinoma of the bladder with glandular differentiation after radical cystectomy: a case report. Urol Case Rep. 2017;15:11–13. doi:10.1016/j.eucr.2017.08.00128932689
   PubMedGoogle Scholar
• Chen HM, Pan CC, Tsai CM, et al. Concomitant primary lung cancer and metastatic pulmonary colorectal cancer that responded to gemcitabine/cisplatin/bevacizumab combination therapy. J Cancer Res Pract. 2015;2(1):76–82.
   Google Scholar
• Agnès D, Sophie C, Nuria K, et al. Gemcitabine-based chemotherapy in sarcomas: a systematic review of published trials. Crit Rev Oncol Hematol. 2016;98:73–80. doi:10.1016/j.critrevonc.2015.10.02026555460
   PubMedGoogle Scholar
• Wang YF, Wang SL, Liu JH, et al. Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways. Chem Biol Interact. 2018;290:44–51. doi:10.1016/j.cbi.2018.05.00729782821
   PubMedGoogle Scholar
• Patrizia G, Gregory RP, Guru S, et al. The impact of adding taxanes to gemcitabine and platinum chemotherapy for the first-line therapy of advanced or metastatic urothelial cancer: a systematic review and meta-analysis. Eur Assoc Urol. 2016;69:624–633. doi:10.1016/j.eururo.2015.09.051
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang LJ, Bai XG, et al. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer. Biomed Pharmacother. 2018;106:1307–1316. doi:10.1016/j.biopha.2018.07.08330119201
   PubMed Web of Science ®Google Scholar
• Fan ML, Liang XF, Li ZH, et al. Chlorambucil gemcitabine conjugate nanomedicine for cancer therapy. Eur J Pharm Sci. 2015;79:20–26. doi:10.1016/j.ejps.2015.08.01326342774
   PubMedGoogle Scholar
• Sun M, Zhao WY, Xie QP, et al. Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer. Surg Oncol. 2015;24:28–34. doi:10.1016/j.suronc.2014.11.00225434982
   PubMed Web of Science ®Google Scholar
• Yang CG, Song WT, Zhang SW, et al. Poly (L-glutamic acid)-g-methoxy poly (ethylene glycol)-gemcitabine conjugate improves the anticancer efficacy of gemcitabine. Int J Pharm. 2018;550:79–88. doi:10.1016/j.ijpharm.2018.08.03730138704
   PubMedGoogle Scholar
• Lionel S, Laurent M, Paul M, et al. Gemcitabine-induced myopathy. Semin Arthritis Rheum. 2014;43:784–791. doi:10.1016/j.semarthrit.2013.11.00924387817
   PubMedGoogle Scholar
• Amit M, Jonathan SL. Gemcitabine-associated acute lipodermatosclerosislike eruption: an underrecognized phenomenon. JAAD Case Reports. 2017;3(3):190–195. doi:10.1016/j.jdcr.2017.02.01428443306
   PubMedGoogle Scholar
• Tahir EY, Sibel IT, Sevgi T. Development and characterization of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs) using central composite design. Int J Pharm. 2018;548:255–262. doi:10.1016/j.ijpharm.2018.06.06329969712
   PubMedGoogle Scholar
• Carlotta B, Fransisca L, Yeonju L, et al. Gemcitabine enhances the transport of nanovector- albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett. 2017;403:296–304. doi:10.1016/j.canlet.2017.06.02628687352
   PubMedGoogle Scholar
• Nuno V, Abigail F, Iva F, et al. Gemcitabine anti-proliferative activity significantly enhanced upon conjugation with cell-penetrating peptides. Bioorg Med Chem Lett. 2017;27:2898–2901. doi:10.1016/j.bmcl.2017.04.08628495087
   PubMedGoogle Scholar
• Gebremariam B, Hamid A, Ehsan S, et al. Nanotechnology for delivery of gemcitabine to treat pancreatic cancer. Biomed Pharmacother. 2017;88:635–643. doi:10.1016/j.biopha.2017.01.07128142120
   PubMedGoogle Scholar
• Zhou Y, Chang QQ, Wang WJ, et al. Sensitive analysis and pharmacokinetic study of a novel gemcitabine carbamate prodrug and its active metabolite gemcitabine in rats using LC-ESI-MS/MS. J Chromatogr B. 2018;1083:249–257. doi:10.1016/j.jchromb.2018.03.015
   PubMed Web of Science ®Google Scholar
• Ravindra DD, Ankit S, Prasoon K, et al. Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine. Eur J Pharm Sci. 2016;93:147–162. doi:10.1016/j.ejps.2016.08.02127531553
   PubMedGoogle Scholar
• Wang ZM, Chen LN, Chu ZY, et al. Gemcitabine-loaded gold nanospheres mediated by albumin for enhanced anti-tumor activity combining with CT imaging. Mater Sci Eng C. 2018;89:106–118. doi:10.1016/j.msec.2018.03.025
   PubMed Web of Science ®Google Scholar
• Arnaud P, Simona M, Semen OY, et al. Squalene versus cholesterol: which is the best nanocarrier for the delivery to cells of the anticancer drug gemcitabine? C R Chim. 2018;21:974–986. doi:10.1016/j.crci.2018.02.008
   Web of Science ®Google Scholar
• Ma L, Chen YC, Wang XD, et al. Design, characterization, and in vitro antiproliferative efficacy of gemcitabine conjugates based on carboxymethyl glucan. Bioorg Med Chem Lett. 2018;28:2920–2924. doi:10.1016/j.bmcl.2018.07.01430017318
   PubMed Web of Science ®Google Scholar
• Yuan Z, Xin B, Bingfang Y, et al. Gemcitabine nanoparticles promote antitumor immunity against melanoma. Biomaterials. 2019;189:48–59. doi:10.1016/j.biomaterials.2018.10.02230388589
   PubMedGoogle Scholar
• Jun YP, Ye LC, Ju RC, et al. Gemcitabine-incorporated G-quadruplex aptamer for targeted drug delivery into pancreas cancer. Mol Ther. 2018;12:543–553. doi:10.1016/j.omtn.2018.06.003
   Web of Science ®Google Scholar
• Jansen WJM, Pinedo HM, Wilt CLVD, et al. The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts. Eur J Cancer. 1995;31(13):2313–2319. doi:10.1016/0959-8049(95)00440-8
   Google Scholar
• Andries MB, Herbert MP, Godefridus JP. Determinants of resistance to 2’,2’-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002;5:19–33.12127861
   PubMed Web of Science ®Google Scholar
• Vaibhav K, Smit K, Noor A, et al. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. Int J Pharm. 2014;470:51–62. doi:10.1016/j.ijpharm.2014.05.00524810239
   PubMedGoogle Scholar
• Jin SM, Wang YN, Zhu HM, et al. Nanosized aspirin-Arg-Gly-Asp-Val: delivery of aspirin to thrombus by the target carrier Arg-Gly-Asp-Val tetrapeptide. ACS Nano. 2013;7(9):7664–7673. doi:10.1021/nn402171v23931063
   PubMed Web of Science ®Google Scholar
• Yu HL, Mei SH, Zhao M, et al. RGD-peptides modifying dexamethasone: to enhance the anti-inflammatory efficacy and limit the risk of osteoporosis. Med Chem Comm. 2015;6:1345–1351. doi:10.1039/C5MD00215J
   Google Scholar
• Wu JH, Zhu HM, Zhao M, et al. IQCA-TASS: a nano-scaled P-selectin inhibitor capable of targeting thrombus and releasing IQCA/TARGD(S)S in vivo. J Mater Chem B. 2017;5:917–927. doi:10.1039/C6TB02705A
   PubMed Web of Science ®Google Scholar
• P J L, Charles D. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta. 2007;1776:138–159. doi:10.1016/j.bbcan.2007.07.00417881132
   PubMedGoogle Scholar